The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Divergent CSF alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy
Open accessAbstract
BACKGROUND: Elevated CSF τ is considered a biomarker of neuronal injury in newly developed Alzheimer's disease (AD) and mild cognitive impairment (MCI) criteria. However, previous studies have failed to detect alterations of τ species in other primary tauopathies. We assessed CSF τ protein abnormalities in AD, a tauopathy with prominent Aβ pathology, and progressive supranuclear palsy (PSP), a primary tauopathy characterised by deposition of four microtubule-binding repeat (4R) τ with minimal Aβ pathology. METHODS: 26 normal control (NC), 37 AD, and 24 patients with PSP participated in the study. AD and PSP were matched for severity using the clinical dementia rating sum of boxes (CDR-sb) scores. The INNO BIA AlzBio3 multiplex immunoassay was used to measure CSF Aβ, total τ, and ptau181. Additional, novel ELISAs targeting different N-terminal and central τ epitopes were developed to examine CSF τ components and to investigate interactions between diagnostic group, demographics and genetic variables. RESULTS: PSP had lower CSF N-terminal and C-terminal τ concentrations than NC and AD measured with the novel τ ELISAs and the standard AlzBio3 τ and ptau assays. AD had higher total τ and ptau levels than NC and PSP. There was a gender by diagnosis interaction in AD and PSP for most τ species, with lower concentrations for male compared to female patients. CONCLUSIONS: CSF τ fragment concentrations are different in PSP compared with AD despite the presence of severe τ pathology and neuronal injury in both disorders. CSF τ concentration likely reflects multiple factors in addition to the degree of neuronal injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Experimental — accuracy not yet measuredIn the citing paper
“CSF tau levels are not increased in non-AD tauopathies57–60, suggesting that extracellular tau is not a primary target in these conditions.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,680
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071
Delis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Self-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,925
California Verbal Learning Test
Delis, D. C., Freeland, J., Kramer, J. H., & Kaplan, E. (1987) · PsycTESTS Dataset · doi:10.1037/t48844-000 · Cited by 1,450
Self-citationCalifornia verbal learning test-second edition
Delis, D. C. (2000) · Medical Entomology and Zoology · Cited by 769
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574
Kramer, J. H., Jurik, J., Sha, S. J., Rankin, K., Rosen, H. J., Johnson, J. K., & Miller, B. L. (2003) · Cognitive and Behavioral Neurology · doi:10.1097/00146965-200312000-00002 · Cited by 507
Self-citationHall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
WECHSLER ADULT INTELLIGENCE SCALE
Maharani, N. D., Nur Azizah Maulidyah, A. R., Maghfiroh, N. A., & Eva, N. (2021) · Flourishing Journal · doi:10.17977/um070v2i12022p32-37 · Cited by 417
Neurochemical Aftermath of Amateur Boxing
Zetterberg, H., Hietala, M. A., Jonsson, M. A. G., Andreasen, N., Styrud, E., Karlsson, I., Edman, Å., Popa, C., Rasulzada, A., Wahlund, L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1277 · Cited by 366
Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351
Behavioral disorders in the frontal and temporal variants of frontotemporal dementia
Liu, W., Miller, B. L., Kramer, J. H., Rankin, K., Wyss-Coray, C., Gearhart, R., Phengrasamy, L., Weiner, M., & Rosen, H. J. (2004) · Neurology · doi:10.1212/01.wnl.0000113729.77161.c9 · Cited by 313
Self-citationDamoiseaux, J. S., Seeley, W. W., Zhou, J., Shirer, W. R., Coppola, G., Karydas, A., Rosen, H. J., Miller, B. L., Kramer, J. H., Greicius, M. D., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0305-12.2012 · Cited by 267
Self-citationBiological markers for therapeutic trials in Alzheimer’s disease
Frank, R., Galasko, D., Hampel, H. J., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 254
Scherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249
Self-citationCoppola, G., Chinnathambi, S., Lee, J. J., Dombroski, B. A., Baker, M. C., Soto-Ortolaza, A. I., Lee, S. E., Klein, E., Huang, A. Y., Sears, R., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds161 · Cited by 240
Self-citationPossin, K., Laluz, V., Alcantar, O., Miller, B., & Kramer, J. (2010) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2010.10.026 · Cited by 231
Self-citationThe Delis-Kaplan Executive Function System
Swanson, J. (2005) · Canadian Journal of School Psychology · doi:10.1177/0829573506295469 · Cited by 220
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Self-citationMaia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Arai, T., Ikeda, K., Akiyama, H., Nonaka, T., Hasegawa, M., Ishiguro, K., Iritani, S., Tsuchiya, K., Iseki, E., Yagishita, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10793 · Cited by 193
Extracellular Tau Levels Are Influenced by Variability in Tau That Is Associated with Tauopathies
Karch, C. M. M., Jeng, A. T., & Goate, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380642 · Cited by 185
Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease
Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175
Progressive supranuclear palsy
Gearing, M., Olson, D. A., Watts, R. L., & Mirra, S. S. (1994) · Neurology · doi:10.1212/wnl.44.6.1015 · Cited by 120
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy
Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., Calabresi, P., Spillantini, M. G., Padovani, A., & Luca, M. D. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.009 · Cited by 101
Urakami, K., Wada, K., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ishizu, H., Kashihara, K., Yamamoto, M., Tsuchiya-Ikemoto, K., et al. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00480-9 · Cited by 97
Rosso, S. M., van Herpen, E., Pijnenburg, Y. A. L., Schoonenboom, N. S. M., Scheltens, P., Heutink, P., & Swieten, J. C. V. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1209 · Cited by 78
Noguchi, M., Yoshita, M., Matsumoto, Y., Ono, K., Iwasa, K., & Yamada, M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.015 · Cited by 73
Constantinescu, R., Zetterberg, H., Holmberg, B., & Rosengren, L. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.001 · Cited by 65
Luk, C. Y., Compta, Y., Magdalinou, N. K., Martı́, M. J., Hondhamuni, G., Zetterberg, H., Blennow, K., Constantinescu, R., Pijnenburg, Y. A. L., Mollenhauer, B., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07911.x · Cited by 65
Boxer, A. L., Gold, M., Huey, E. D., Hu, W. T., Rosen, H. J., Kramer, J. H., Gao, F., Burton, E. A., Chow, T. W., Kao, A. W., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.03.003 · Cited by 55
Self-citationJohansson, A., Zetterberg, H., Håkansson, A. S., Nissbrandt, H., & Blennow, K. (2005) · Neurodegenerative Diseases · doi:10.1159/000086428 · Cited by 23
The relationship between clinical and pathological variables in Richardson’s syndrome
Schofield, E. C., Hodges, J. R., Bak, T. H., Xuereb, J. H., & Halliday, G. M. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6205-8 · Cited by 22
Analysis of Human Tau in Cerebrospinal Fluid
Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17
Cited by
Sorted by citations
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485
Self-citationTau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
Schöll, M., Maaß, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. J. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 248
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
Metadata
- Authors
- Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., Tartaglia, M. C., Miller, Z., Coppola, G., Ahlijanian, M., Soares, H., Kramer, J. H., Rabinovici, G. D., Rosen, H. J., Miller, B. L., Meredith, J., & Boxer, A. L.
- Affiliations
- University of California, San Francisco (US)
- Bristol-Myers Squibb (United States) (US)
- University of California, Los Angeles (US)
- Corresponding author
- Boxer, A. L.
- ORCID
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2014-06-04
- Volume
- 86
- Issue
- 3
- Pages
- 244-250
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC4256124
- OpenAlex
- W2133759450
- Cited by
- 132
- References
- 47
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 18 · 2023: 5 · 2022: 15 · 2021: 17 · 2020: 7 · 2019: 16 · 2018: 13 · 2017: 14 · 2016: 10 · 2015: 4 · 2014: 3
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (K23-AG031861)
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Hellman Family Foundation
- TauRx Pharmaceuticals
- Elan
- Kyowa Hakko Kirin
- H. Lundbeck A/S
- National Institutes of Health (AG19724)
- Genentech
- Avid Radiopharmaceuticals
- National Institute on Aging (AG031861, AG23501, R01AG022983, AG-19724, R01AG031278, K23AG031861, K24AG045333, R01AG038791, P01AG019724, R01AG032289, P50AG023501)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- tauopathy, Alzheimer's disease, progressive supranuclear palsy, cerebrospinal fluid tau, phosphorylated tau 181, amyloid-beta, 4R tau, sex differences, biomarkers, neuronal injury
- MeSH terms
- Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Mental Status Schedule, Middle Aged, Neuropsychological Tests, Peptide Fragments, Phosphorylation, Prognosis, Reference Values, Supranuclear Palsy, Progressive, Biomarkers, Amyloid beta-Peptides, tau Proteins, Tauopathies, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
